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Abstract
Background: For patients with mid and distal rectal cancer, robust evidence on long-term outcome and causal
treatment effects of transanal total mesorectal excision (TaTME) is lacking. This multicentre retrospective cohort
study aimed to assess whether TaTME reduces locoregional recurrence rate compared to laparoscopic total
mesorectal excision (LapTME).
Methods: Consecutive patients with rectal cancer within 12 cm from the anal verge and clinical stage II-III were
selected from three institutional databases. Outcome after TaTME (Nov 2011 - Feb 2018) was compared to a
historical cohort of patients treated with LapTME (Jan 2000 - Feb 2018) using the inverse probability of treatment
weights method. The primary endpoint was three-year locoregional recurrence.
Results: A total of 710 patients were analysed, 344 in the TaTME group and 366 in the LapTME group. At 3 years,
cumulative locoregional recurrence rates were 3.6% (95% CI, 1.1–6.1) in the TaTME group and 9.6% (95% CI, 6.5–
12.7) in the LapTME group (HR = 0.4; 95% CI, 0.23–0.69; p = 0.001). Three-year cumulative disease-free survival rates
were 74.3% (95% CI, 68.8–79.8) and 68.6% (95% CI, 63.7–73.5) (HR = 0.82; 95% CI, 0.65–1.02; p = 0.078) and three-year
overall survival 87.2% (95% CI, 82.7–91.7) and 82.2% (95% CI, 78.0–86.2) (HR = 0.74; 95% CI, 0.53–1.03; p = 0.077),
respectively. In patients who underwent sphincter preservation procedures, TaTME was associated with a
significantly better disease-free survival (HR = 0.78; 95% CI, 0.62–0.98; p = 0.033).
Conclusions: These findings suggest that TaTME may improve locoregional recurrence and disease-free survival
rates among patients with mid and distal locally advanced rectal cancer.
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Background
Each year, 125,000 new cases of rectal cancer are diag-
nosed in the European Union [1] and mortality ranges
between 4 and 10/100,000 per year. The therapeutic ap-
proach to rectal cancer is eminently multidisciplinary,
but surgery remains the main cornerstone for cure. For
mid- and low rectal tumours, total mesorectal excision
(TME) along embryological-specific planes is the stand-
ard surgical treatment [2]. An intact specimen based on
the principles of TME grading, the circumferential resec-
tion margin, and the distal resection margin have be-
come the most critical factors in predicting the risk of
locoregional recurrence and long-term survival [3–5].
Primary rectal cancer surgery can be performed
through an open, laparoscopic, robotic, or transanal ap-
proach. The oncological superiority of one approach
over the other is still a topic of debate. A recent meta-
analysis showed that the risk of a suboptimal TME spe-
cimen is higher with laparoscopy compared to open sur-
gery [6]. The transanal TME (TaTME) was developed to
improve patient outcomes and the quality of the dissec-
tion, which is believed to be especially significant in
mid- and low rectal tumours. Studies published to date
have reported mesorectal excision completeness rates as
high as 92.5 to 96%, and an even significantly higher rate
of complete and near-complete mesorectal excisions
compared to conventional laparoscopic TME (LapTME)
[7–9]. These clinical findings suggest that TaTME is a
highly promising technique, although the translation of
this data into improved mid- and long-term oncological
outcomes has yet to be proven. Unexpectedly, a recent
study reported a pattern of rapid and multifocal locore-
gional recurrence after TaTME [10]. Therefore, this
multicenter international study was designed with the
goal of comparing the three-year oncological outcome of
patients with primary locally advanced rectal cancer




Data were obtained from one Spanish center, the Hos-
pital Clinic of Barcelona, and two Dutch centers, the
Gelderse Vallei Hospital and the Amsterdam UMC at
AMC. LapTME was first introduced at the Hospital
Clinic in 1994. In November 2011, TaTME became the
standard of care for all patients presenting with rectal
cancer that did not require abdominoperineal resection
or pelvic exenteration. In February 2017, the transanal
approach became standard for patients requiring an
abdominoperineal resection. Gelderse Vallei Hospital is
a high-volume rectal cancer institution in which TaTME
was first used in 2012. At the Amsterdam UMC TaTME
became the standard procedure for patients presenting
with mid- and low rectal cancer from 2014 onwards. All
patients with histologically proven rectal adenocarcin-
oma treated by TaTME were prospectively registered in
a local standardised database or in the International
TaTME Registry [11]. Consequently, a multicenter data-
base was created, which included the TaTME cohort
and a cohort of patients treated by LapTME between
January 2000 and February 2018, through a retrospective
analysis of clinical records. All three hospitals used
TaTME as a standard procedure for patients with
mid- and low rectal cancer until their recent partici-
pation in the COLOR III trial, a randomised study in
which participants are allocated to either TaTME or
LapTME [12].
For this analysis, adult patients with a solitary locally
advanced rectal adenocarcinoma, according to the ACO-
SOG Z6051 definition (cT3/cT4, or cN1/cN2 with any
cT) detected by magnetic resonance imaging (MRI) with
or without transrectal ultrasonography, within 12 cm of
the anal verge treated with TaTME or LapTME were in-
cluded [13]. The exclusion criteria were: patients with
cTisN0 or cT1-2 N0; pelvic malignancy within 5 years;
severe, incapacitating disease, i.e. American Society of
Anaesthesiologists (ASA) classification IV-V; procedures
performed in an emergency setting; tumours previously
treated by local excision; unknown cT or cM; metastatic
tumours (M1); synchronous tumours; active Crohn’s or
ulcerative colitis; familial risk-colorectal cancer syn-
dromes; and patients with 30-day mortality when it was
judged to have occurred as a direct result of a major ac-
tive postoperative complication, which is not of primary
interest. The Institutional Ethics Committees (Comité de
Ética de la Investigación con Medicamentos, Beoor-
dlingscommissie Wetenschappelijk Onderzoek, and
Medisch Ethische Toetsings Commissie AMC) approved
the TaTME and LapTME techniques years prior to this
study in the three institutions noted, and the current
study protocol was assessed and accepted by the local
Institutional Review Boards. Patients provided written
informed consent.
Endpoints
The primary endpoint was three-year locoregional recur-
rence. Secondary endpoints included systemic recur-
rence, disease-free survival, and overall survival.
Procedures and definitions
The specific staging, classification methods, and surgical
procedures have been described in more detail previ-
ously [14–16]. Tumours were considered high if the dis-
tal border of the tumour was > 10 cm from the anal
verge, mid if it was between 5 and 10 cm, and low in
case of a distal border < 5 cm. Patients were eligible for
neoadjuvant therapy in cases of cT3b-d/cT4 or cN-
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positive tumours below the peritoneal reflection, or if
the circumferential resection margin was threatened or
involved, although other factors such as extramural ven-
ous invasion were also taken into account and discussed
by a multidisciplinary team. The indication to receive
radiotherapy alone or in combination with chemother-
apy was given depending on the institution-specific pro-
tocols. Short-course one-week radiotherapy was
administered by 25 Gy in five daily fractions. Neoadju-
vant long-course chemoradiotherapy was administered
by continuous 5-fluorouracil (5-FU) infusion (225 mg/
m2 for 5 days per week) or capecitabine (825 mg/m2
twice daily for 5 days per week), and a total dosage of 45
Gy, by a weekly dose of 9 Gy divided in 5 days each
week, for a total of 5 weeks. The interval between com-
pletion of long-course chemoradiotherapy and surgery
was 5 to 7 weeks at the beginning of the LapTME cohort
recruitment, and, in accordance with current guidelines,
was subsequently extended up to 12 weeks and associ-
ated with appropriate restaging [1].
The mesorectal specimen was analysed on the basis of
four major pathological factors: the integrity of the mesor-
ectum, graded following the Quirke method: complete,
near-complete, or incomplete [5]; the circumferential re-
section margin, considered to be positive when the dis-
tance between the deepest portion of the tumour and the
resection margin was ≤1mm, or in the case of a positive
lymph node at ≤1mm of the radical dissection plane; the
distal resection margin, considered to be positive if
tumour cells were present ≤1mm from the lower border
of the tumour to the cut edge of the specimen; and the
number of lymph nodes harvested. Pathological tumour
response to neoadjuvant therapy was scored by the Ryan
tumour regression grade (three-point TRG): TRG 1, no vi-
able cancer cells, or single cells or small groups of cancer
cells; TRG 2, residual cancer outgrown by fibrosis; and
TRG 3, significant fibrosis outgrown by cancer, or no fi-
brosis with extensive residual cancer [17].
Follow-up
Until follow-up was completed after 5 years, patients vis-
ited every 3 to 6months during the first 2 years and every
6 to 12months during the remaining 3 years. Visits in-
cluded a history, physical evaluation with digital rectal
examination, and determination of the carcinoembryonic
antigen level. In Barcelona, imaging studies with thoracic
and abdominopelvic CT scans were requested every 6
months during the first 2 years and annually during the
remaining 3 years. In both Gelderse Vallei and Amsterdam
UMC, imaging study was based on liver ultrasound, and
CT scan was performed in case of suspicion of local recur-
rence or distant metastasis. Pelvic MRI and/or transrectal
ultrasound-guided needle biopsy were requested when
pelvic recurrence was suspected. Locoregional recurrence
was defined as any recurrence in the pelvic area and had
to be confirmed at least on imaging.
Statistical analysis
Qualitative variables were expressed as absolute frequen-
cies and percentages. Quantitative variables were re-
ported as means or medians with their 95% confidence
intervals (CI), except for follow-up periods, which were
expressed as median with range. To allow for an un-
biased comparison, an inverse probability of treatment
weights approach was used [18]. A logistic regression
model was applied, including demographic and clinical
preoperative variables such as hospital, age, gender, ASA
classification, body mass index (BMI), the distance of the
tumour from the anal verge, cT and cN stage, and base-
line threatened or involved circumferential resection
margin. As the goal was to develop a balanced popula-
tion that was independent of the outcome assessment,
postoperative variables were not included, except for
relevant variables that were assessable only after surgery
(i.e., pT and pN stage, and pathological response to neo-
adjuvant therapy). The covariate radiologic extramural
venous invasion was excluded from the model due to a
significant amount of missing data because this informa-
tion was not routinely reported until recent years. The
covariate type of surgery (categorised as sphincter-saving
or abdominoperineal resection) could not be included in
the propensity score calculation due to the small num-
ber of abdominoperineal resections in the TaTME
group.
A well-balanced distribution of the covariates in the
weighted sample was confirmed by means standardised
differences meeting a standard objective of ±0.10 [19].
The only exception was the covariate hospital, in which
a standardised difference of 0.12 was achieved. Since
some authors consider the cut-off point for standardised
differences to be ±0.20, and given the extensive homo-
geneity of the rest of covariates (with standardised differ-
ences of less than ±0.02), this was finally accepted [20].
The estimation of the survival functions was carried
out using the Kaplan-Meier method. The estimation of
the effect of surgical procedure was performed using
Cox hazard models weighted by the inverse probability
of treatment weight adjusting by preservation of the
sphincter (sphincter-saving surgery or abdominoperineal
resection) with a cut-off at 3 years. Additional analyses
using Accelerated Failure Time models were used for
the analysis of time to event data in order to estimate
the time ratio (TR) for the effect of the surgical proced-
ure on acceleration in the time to the event [21].
Statistical tests were two-sided with a 5% type I error.
All the analyses were carried out using SPSS version 25
(IBM) or SAS version 9.4 (SAS Institute, Inc., Cary,
North Carolina).
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Results
Between 2000 and 2018, 863 patients with primary lo-
cally advanced rectal adenocarcinoma met the inclusion
criteria and were eligible. Of these, 153 (17.7%) were ex-
cluded because data were missing in the covariates se-
lected for the inverse probability of treatment weight.
This occurred mainly at the beginning of the LapTME
cohort, because either systematization in reporting all
the information was scarce, or the necessary investiga-
tions to obtain that data were not always performed in
that period. Therefore, the final study population con-
sisted of 710 patients, of whom 344 (48.5%) underwent
TaTME and 366 (51.5%) LapTME (Fig. 1). The median
follow-up in the TaTME and LapTME cohorts was 28.4
(range 0.1–83.6) and 61.1 (range 1.1–205.7) months, re-
spectively. After truncation at 3 years, more than 30% of
the patients remained at risk in both groups. Table 1
shows the selected covariates of patients treated with
TaTME or LapTME, with standardised differences be-
fore and after the inverse probability of treatment
weight.
In both groups, similar rates of neoadjuvant therapy
administration were observed (71.2% vs. 77.0%; p =
0.086). Short-course radiotherapy was given to 59
(24.5%) patients in the TaTME cohort and to 79 (28.1%)
patients in the LapTME cohort (p = 0.408), while most
patients in both groups received long-course chemora-
diotherapy: 180 (52.3%) vs. 203 (55.4%) (p = 0.371).
TaTME was associated with a significant reduction in
abdominoperineal resection rates: 2.9% vs. 25.6%, p <
0.001. Similar rates of 30-day postoperative complica-
tions were observed (31.9% vs. 35.2%; p = 0.382).
Histopathological outcomes and adjuvant therapy
Despite an absence of significant differences in the ori-
ginal multi-category mesorectal specimen variable, a
Fig. 1 Flow diagram of study population. Abbreviations: TME, total mesorectal excision; AMC, Amsterdam University Medical Centers; ASA,
American Society of Anesthesiologists; BMI, body mass index; CRM, circumferential resection margin; NAT, neoadjuvant therapy; LapTME,
laparoscopic total mesorectal excision; TaTME, transanal total mesorectal excision
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Table 1 Selected covariates of patients treated with laparoscopic or transanal total mesorectal excision for rectal cancer, with
standardised differences before and after inverse probability of treatment weighting
Variable Surgical approach Standardised differences
TaTME, No. (%) LapTME, No. (%) Before IPTW After IPTW
Total, No. 344 366
Center
Barcelona 194 (56.4) 212 (57.9) 0.1189 0.1238
Gelderse Vallei 90 (26.1) 79 (21.5)
AMC 60 (17.4) 75 (20.4)
Age, years (mean, 95% CI) 66.5 (65.2–67.7) 66.4 (65.2–67.6) 0.0071 < 0.0001
Gender
Female 104 (30.2) 137 (37.4) 0.1526 −0.007
Male 240 (69.7) 229 (62.5)
ASA
I 44 (12.7) 68 (18.5) 0.0682 0.0002
II 239 (69.4) 227 (62.0)
III 61 (17.7) 71 (19.4)
BMI, kg/m2 (mean, 95% CI) 25.5 (25.1–25.9) 26.4 (25.7–27.0) −0.161 −0.017
Distance from AV, cm (mean, 95% CI) 7.2 (6.9–7.5) 6.5 (6.1–6.8) 0.2487 0.0024
Clinical T-stage
cT1 0 (0.0) 4 (1.1) 0.0726 0.0047
cT2 27 (7.8) 41 (11.8)
cT3 289 (84.0) 266 (76.6)
cT4 28 (8.1) 35 (10.0)
Clinical N-stage
cN0 148 (43.0) 113 (30.8) −0.288 0.0005
cN1 155 (45.0) 181 (49.4)
cN2 41 (11.9) 72 (19.6)
Baseline threatened/involved CRM 94 (27.3) 101 (27.6) −0.006 −0.009
Pathologic response to NATa
TRG 1 93 (38.2) 103 (36.5) −0.144 −0.003
TRG 2 76 (31.2) 85 (30.1)
TRG 3 74 (30.4) 94 (33.3)
Pathological T-stage −0.144 −0.003
pT0 40 (11.6) 35 (9.5) −0.144 −0.003
pTis 1 (0.2) 0 (0.0)
pT1 26 (7.5) 20 (5.4)
pT2 85 (24.7) 95 (25.9)
pT3 179 (52.0) 179 (48.9)
pT4 13 (3.7) 37 (10.1)
Pathological N-stage
pN0 251 (72.9) 243 (66.3) −0.144 −0.003
pN1 57 (16.5) 76 (20.7)
pN2 33 (9.5) 47 (12.8)
Variable Surgical approach Standardised differences
TaTME, No. (%) LapTME, No. (%) Before IPTW After IPTW
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significant higher rate of complete or near-complete was
observed in the TaTME cohort: 98.5% vs. 93.5%, p =
0.0003. The rate of circumferential resection margin in-
volvement and incidence of intra-operative rectal perfor-
ation were also lower in the TaTME group (Table 2).
These findings translated into an overall better compos-
ite endpoint of poor pathological outcome for TaTME.
Survival and recurrence analyses
Three years after surgery, the rates of locoregional recur-
rence were 3.6% in the TaTME group and 9.6% in the
LapTME group Hazard Ratio (HR) = 0.4 (95% CI, 0.23–
0.69; p = 0.001) (Fig. 2). After stratifying for sphincter-
saving surgery or abdominoperineal resection, a lower
rate of locoregional recurrence was maintained in those
patients who underwent TaTME with sphincter preser-
vation HR = 0.42 (95% CI, 0.24–0.73; p = 0.002). No dif-
ference was observed in patients with low rectal cancer
HR = 0.9 (95% CI, 0.28–2.93; p = 0.866). In patients with
cancer of the mid rectum, the rates of locoregional re-
currence were 5.3% in de TaTME group and 12.3% in
the LapTME group HR = 0.39 (95% CI, 0.2–0.76; p =
0.006). Systemic metastases were reported in 16.4% of
the patients in the TaTME group and in 19.8% of the
patients in the LapTME group HR = 0.93 (95% CI, 0.7–
1.24; p = 0.615).
At 3 years, the disease-free survival rates were 74.3% in
the TaTME group and 68.6% in the LapTME group
HR = 0.81 (95% CI, 0.65–1.02; p = 0.078) (Fig. 3). How-
ever, when the analysis was limited to patients with
sphincter preservation, an improved disease-free survival
was observed in patients who underwent TaTME HR =
0.78 (95% CI, 0.62–0.98; p = 0.033). The overall survival
rates were 87.2% in the TaTME group and 82.2% in the
LapTME group HR = 0.74 (95% CI, 0.53–1.03; p =
0.076). Significant differences in overall survival could
not be demonstrated in patients who underwent TaTME
with sphincter preservation HR = 0.73 (95% CI, 0.52–
1.02; p = 0.068). The survival and recurrence subgroup
analyses are shown in Fig. 4.
Within 3 years after primary rectal cancer surgery, 35
locoregional recurrences were observed in the LapTME
cohort, with a corresponding number of 12 in the
TaTME cohort. Of those patients, 25 (six in the TaTME
group and 19 in the LapTME group) presented with at
least one of the following risks factors: T4 tumour, N2
disease, incomplete mesorectal specimen, or positive cir-
cumferential resection margin. The median time to
locoregional recurrence could not be calculated since
the event rate was less than 50%. However, the Acceler-
ated Failure Time analysis identified a longer time-ratio
in the TaTME group TR = 2.3 (CI, 1.34–4.00; p = 0.026).
No multifocal pattern of recurrence was diagnosed.
Discussion
In this multicenter cohort of 710 patients with clinical
stage II-III rectal adenocarcinoma, TaTME provided a
three-year 60% risk reduction for locoregional recur-
rence compared to LapTME. In patients undergoing sur-
gery with sphincter preservation, the three-year disease-
free survival rate was higher for patients treated with
TaTME than for patients treated with LapTME. These
benefits could be explained by an improved quality of
the mesorectal specimen, with fewer positive resection
margins, and lower rate of rectal perforations [4, 22, 23].
The performance of an optimal TME is technically de-
manding, and the histopathological equivalence of the
laparoscopic and open approaches has been recently
questioned [13, 24]. Fleshman et al. compared LapTME
to open TME and included similar patients as the
current study, except for the fact that every patient re-
ceived neoadjuvant therapy. They found that LapTME
did not meet the criteria for noninferiority in a compos-
ite score of complete or near-complete TME, and nega-
tive circumferential and distal resection margins [13]. It
is important to note that Fleshman et al. did not find
any difference in survival within 2 years after surgery
[25]. Still, the study was not designed as an equivalence
trial for survival and recurrence, and the absence of nu-
merical distinctions might not be indicative of any
dissimilarity.
Table 1 Selected covariates of patients treated with laparoscopic or transanal total mesorectal excision for rectal cancer, with
standardised differences before and after inverse probability of treatment weighting (Continued)
Variable Surgical approach Standardised differences
TaTME, No. (%) LapTME, No. (%) Before IPTW After IPTW
pN3 0 (0.0) 0 (0.0)
pN1c 3 (0.8) 0 (0.0)
Sphincter saving surgeryb 334 (97.0) 272 (74.3) NA NA
Abbreviations: TaTME, transanal total mesorectal excision; LapTME, laparoscopic total mesorectal excision; IPTW, inverse probability of treatment weighting; AMC,
Amsterdam University Medical Centers; ASA, American Society of Anesthesiologists; BMI, body mass index; AV, anal verge; CRM, circumferential resection margin;
NAT, neoadjuvant therapy; TRG, tumour regression grade; NA, not applicable
a Including only patients treated with NAT. The TRG system developed by Ryan et al. was used17
b Not included in the IPTW calculation due to the large differences between groups. It was used as an adjustment cofactor in Cox models
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Nevertheless, several clinical studies and meta-analyses
have reported improved histopathological outcomes with
TaTME compared to LapTME [26, 27]. However, the
translation of these potentially advantageous data into
improved mid- and long-term oncological outcomes is
still scarce. The outcomes of the present study indicate
that TaTME not only allows patients to benefit from the
short-term advantages of minimally invasive surgery, but
might also be superior in ensuring mid-term locoregio-
nal recurrence and disease-free survival in selected
patients.
The reported improvement in locoregional recurrence
rates was at the expense of patients with cancer of the
mid rectum, but unexpectedly this was not confirmed in
patients with cancer of the low rectum. This apparent
disparity could be explained by a high proportion of pa-
tients, not estimable due to retrospective access to the
data, in the LapTME group with low rectal tumours who
underwent open perineal dissection using the transanal
way to facilitate the most challenging part of the proced-
ure. According to a randomised trial, transanal perineal
dissection has been shown to decrease the risk of
Table 2 Pathologic and adjuvant therapy outcomes after inverse probability of treatment weighting
Variable Surgical approach P Value
TaTME, No. (%) LapTME, No. (%)
Total, No. 344 366
AJCC pathological stage
0 38 (11.0) 32 (8.7) 0.8616
I 90 (26.1) 92 (25.1)
II 123 (35.7) 119 (32.5)
III 93 (27.0) 123 (33.6)
IV 0 (0.0) 0 (0.0)
Mesorectal specimen
Complete 318 (93.2) 242 (89.3) 0.1678
Near-complete 20 (5.8) 13 (4.8)
Incomplete 3 (0.8) 16 (5.9)
Distance to CRM, mm (median, 95% CI) 10.0 (10.0–12.0) 7.5 (6.0–10.0) 0.0131
CRM involvement 32 (9.5) 56 (16.2) 0.0038
Distance to DRM, mm (median, 95% CI) 20.0 (20.0–25.0) 19.5 (15.0–20.0) 0.248
DRM involvement 6 (1.8) 7 (2.0) 0.6135
Rectal perforation 2 (0.8) 8 (3.2) 0.0262
Composite poor pathological outcomea 35 (10.6) 69 (24.7) < 0.001
Perineural invasion 44 (13.0) 47 (18.3) 0.0109
Lymphovascular invasion 68 (21.4) 44 (17.0) 0.0182
Budding
no 155 (82.8) 38 (52.7) 0.0002
low 23 (12.3) 32 (44.4)
moderate 2 (1.0) 0 (0.0)
high 7 (3.7) 2 (2.7)
Differential grade 0.5589
good 20 (6.3) 15 (4.8) 0.5589
moderate 254 (80.3) 240 (77.4)
poor 17 (5.3) 22 (7.1)
Number of lymph node harvested (median, 95% CI) 15.0 (15.0–16.0) 14.0 (14.0–15.0) 0.0133
Adjuvant chemotherapy 42 (12.2) 61 (17.1) 0.0508
Adjuvant radiotherapy 4 (1.1) 15 (4.2) 0.0002
Abbreviations: TaTME, transanal total mesorectal excision; LapTME, laparoscopic total mesorectal excision; AJCC, American Joint Committee on Cancer; CRM,
circumferential resection margin; DRM, distal resection margin
a Complete or near-complete TME, and negative CRM and DRM
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circumferential resection margin involvement by more
than 4-fold compared to a purely abdominal TME [28].
Although further investigation is required, these com-
bined data suggest that the surgical therapy of mid and
low rectal cancer should include a perineal approach.
This might be performed with conventional open
surgical instruments or through TaTME in the low rec-
tum. Given the difficulties of approaching mid rectal
cancers using an open transanal technique (the Transa-
nal Abdominal Transanal (TATA) procedure) and the
inferiority of a pure transabdominal laparoscopic ap-
proach as suggested by the present data, TaTME might
Fig. 2 Three-year locoregional recurrence between TaTME and LapTME in patients with locally advanced rectal cancer. Abbreviations: TaTME,
transanal total mesorectal excision; LapTME, laparoscopic total mesorectal excision; HR, hazard ratio; CI, confidence interval
Fig. 3 Three-year disease-free survival between TaTME and LapTME in patients with locally advanced rectal cancer. Abbreviations: TaTME,
transanal total mesorectal excision; LapTME, laparoscopic total mesorectal excision; HR, hazard ratio; CI, confidence interval
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be the preferred technique when the tumour is in the
mid rectum. Robot assisted transabdominal laparoscopy
might potentially achieve similar results, but this has still
to be confirmed.
Although knowledge in the literature is still scarce
and follow-up periods are relatively short, the re-
ported data that TaTME might be associated with a
lower risk of locoregional recurrence are substantiated
by several observational studies. Tuech et al. analysed
56 consecutive patients with low rectal cancer treated
with TaTME and reported a locoregional recurrence
rate of 1.7% with a median follow-up of 29 months
[29]. Veltcamp Helbach et al. analysed 80 patients
with mid- or low rectal cancer who underwent
TaTME, and the locoregional recurrence rate after 2
years was 2.5% [16]. With a median follow-up of 31.9
months, Lelong et al. reported a 0% locoregional re-
lapse rate [30]. More recently, Hol et al. analysed 159
consecutive patients undergoing TaTME with a
complete and minimum follow-up of 3 years, report-
ing three- and five-year local relapse as low as 2 and
4%, respectively [31].
However, a recent study questioned the oncologic val-
idity of the transanal approach. Larsen et al. reported, on
behalf of the Norwegian Colorectal Cancer Group, that
9.5% of the 110 patients who underwent TaTME pre-
sented with an unexpected pattern of early locoregional
recurrence, characterised by rapid, multifocal growth in
the pelvic cavity and sidewalls [10]. The authors sug-
gested that this atypical pattern of relapse may be a con-
sequence of transanal pursestring failure, with spillage of
the malignant cells that are aerosolised by the transanal
insufflator. However, neither in the present study nor
any of the published studies to date has revealed an un-
expected pattern of recurrence. Moreover, the Acceler-
ated Failure Time analysis of our study identified
Fig. 4 Subgroup analyses of survival and recurrence among patients with locally advanced rectal cancer treated with TaTME or LapTME.
Abbreviations: HR, hazard ratio; CI, confidence interval; APR, abdominoperineal resection; TaTME, transanal total mesorectal excision; LapTME,
laparoscopic total mesorectal excision
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TaTME as a protective factor on patients’ locoregional
recurrence time, suggesting a longer time to pelvic re-
lapse in that group compared to patients treated with
LapTME.
This clinical research study was based on real-
world clinical practice and involved several groups
of surgeons to enhance external validity. However, a
significant limitation is its nonrandomised design.
Observational studies are more susceptible to
biases, even more so with surgical interventions
where the risk of treatment assignment partiality is
increased during the early phase of the learning
curve. To avoid this allocation bias, we decided to
use the inverse probability of treatment weight
method, which has been shown to deliver results
more comparable to an RCT than other techniques
such as propensity score stratification and, unlike
matching, retains most participant data [32]. After
weighting, the covariates of the sample obtained
were well-balanced and independent of treatment
assignment. The only exception was the covariate
type of surgery, which was applied as an adjustment
cofactor in the Cox models. Nevertheless, we were
unable to correct for unknown cofounders, and the
analysis by subgroup depending on the type of sur-
gery should be interpreted with caution due the low
number of abdominoperineal resections in the
TaTME cohort.
Another limitation is the inherent retrospective
design which used historical controls. Besides, the
extramural venous invasion variable could not be
included in the propensity score model due to the
large amount of missing data. This occurred pre-
dominantly in the LapTME group because the
radiological extramural venous invasion has recently
begun to be described. Variables such as budding,
perineural and lymphovascular invasion displayed a
heterogeneous distribution. However, the increased
risk of recurrence that this may carry seems to be
offset across the groups. Nonetheless, despite our
extensive corrections, the presence of cofounders
that might bias the results cannot be excluded. Fi-
nally, a representative non-selected group of pa-
tients who were treated for locally advanced rectal
tumours was included. However, the surgical teams
have extensive experience performing transanal pro-
cedures, and the results may not be generalised to
other clinics that have recently started to perform
TaTME.
Conclusions
The results of this multicenter observational trial sup-
port a possible role for TaTME in improving locore-
gional recurrence and disease-free survival rates
among patients with locally advanced rectal cancer.
Further investigation in a randomised clinical trial is
warranted.
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